Pacira BioSciences' Accounts Payables fell 867.45% to $17.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.7 million, marking a year-over-year decrease of 867.45%. This contributed to the annual value of $19.1 million for FY2024, which is 2188.18% up from last year.
Pacira BioSciences' Accounts Payables amounted to $17.7 million in Q3 2025, which was down 867.45% from $30.1 million recorded in Q2 2025.
Pacira BioSciences' 5-year Accounts Payables high stood at $30.1 million for Q2 2025, and its period low was $7.9 million during Q3 2021.
Moreover, its 5-year median value for Accounts Payables was $15.7 million (2023), whereas its average is $16.2 million.
Per our database at Business Quant, Pacira BioSciences' Accounts Payables crashed by 4796.36% in 2024 and then soared by 15798.26% in 2025.
Over the past 5 years, Pacira BioSciences' Accounts Payables (Quarter) stood at $10.5 million in 2021, then soared by 44.36% to $15.2 million in 2022, then grew by 3.14% to $15.7 million in 2023, then increased by 21.88% to $19.1 million in 2024, then dropped by 7.56% to $17.7 million in 2025.
Its Accounts Payables stands at $17.7 million for Q3 2025, versus $30.1 million for Q2 2025 and $23.2 million for Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value